Implandata announces closing of €3m funding round
27 October 2014
Hannover-based Implandata Ophthalmic Products GmbH has announced the closing of a €3m Series B funding round that included Born2Grow Venture Partners as new investor.
Previous investors, all German companies, Peppermint Charité Beteiligungsfonds, Hannover Beteiligungsfonds, High-Tech Gründerfonds, KfW and a group of business angels completed the Series B funding round.
The funding enables the company to complete the clinical program for CE marking of its first product, to launch further studies for complementary product lines and applications in Germany and abroad, specifically to initiate the first IDE study with Massachusetts Eye and Ear Infirmary, Boston/MA and Kellogg Eye Institute, Ann Arbor/MI. For this purpose and in order to prepare the commercial launch of Implandata’s products in the USA, the company established a fully owned US subsidiary Implandata Ophthalmic Products, Inc., located in Wilmington/DE.
The company plans to start further clinical studies for expansion of product use, for clinical validation of complementary product versions and for integrating its pressure sensing technology platform into other ophthalmic surgical procedures and products.
Implandata is currently conducting the multi-centric ARGOS-02 study with its intraocular pressure sensor for continuous monitoring of glaucoma patients' eye pressure. During cataract surgery Implandata’s pressure sensing implant is placed in front of the artificial intraocular lens, posterior to the iris.
After implantation of the micro sensor the patient’s intraocular pressure can be measured at any chosen frequency, either continuously over the course of 24 hours or on demand at defined time points. Patients can perform measurements by themselves and under normal live conditions. Collected data will be sent via a mobile phone module to the eye doctor’s computer screen, allowing remotely monitoring and managing the patient’s disease and alerting the eye doctor in case of patients uncontrolled intraocular pressure.
Implandata’s intraocular pressure sensor allows close monitoring of the patients disease progression and glaucoma therapy success. Through simple and more frequent measurements of intraocular pressure - which is the key parameter in glaucoma therapy - important information on therapy response is delivered to the eye doctor early on, enabling immediate glaucoma therapy adjustment, contributing to prevention of further vision loss due to uncontrolled intraocular pressure.
Source: Implandata Ophthalmic Products GmbH